Company: IMNN
Filing Date: 2025-05-13
Form Type: S-1/A
Source: 0001641172-25-009814
Chunk: 4

Company: Imunon, Inc.
Filing Date: 2025-05-13
Form: S-1/A
Chunk 4
---
 greater of the Floor Price and the lowest daily dollar volume-weighted average price during the period beginning two full trading days prior to the Adjustment Date and ending on the 10th trading day after the Adjustment Date. Upon any such resulting adjustment of the exercise price of the common warrants, the number of shares of Common Stock issuable under the common warrants will be increased such that the aggregate exercise price of a common warrant (adjusted for any exercises by a holder prior to this adjustment) will remain unchanged following such adjustment. As a result, the aggregate number of shares of Common Stock underlying all of the common warrants may increase from 15,000,000 up to 150,000,000 (in each case, based on an assumed public offering price of $0.80 per share), assuming full adjustment of the exercise price to the Floor Price and before giving effect to the “alternative cashless exercise” provision. Assuming full adjustment of the exercise price to the Floor Price, the aggregate number of shares of Common Stock issuable upon the exercise of all of the common warrants pursuant to the “alternative cashless exercise” provisions therein would be 450,000,000 (based on an assumed public offering price of $0.80 per share). In the event that we are unable to obtain Stockholder Approval, the common warrants will not be exercisable and therefore will have no value.

We are also offering to certain purchasers whose purchase of shares of Common Stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, pre-funded warrants, in lieu of shares of Common Stock that would otherwise result in such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock. The public offering price of each pre-funded warrant and accompanying common warrant will be equal to the price at which one share of Common Stock and accompanying common warrant is sold to the public in this offering, minus $0.0001, and the exercise price of each pre-funded warrant will be $0.0001 per share. The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The pre-funded warrants and common warrants are immediately separ